Preadmission SSRI use ups stroke mortality in diabetes

Preadmission SSRI use ups stroke mortality in diabetes

(HealthDay)—For patients with diabetes, preadmission selective serotonin reuptake inhibitor (SSRI) use is associated with increased risk of stroke mortality, according to a study published online May 3 in the Journal of Internal Medicine.

Morten Würtz, M.D., Ph.D., from Aarhus University Hospital in Denmark, and colleagues examined the correlation between preadmission SSRI use and mortality in patients with diabetes who were hospitalized due to stroke. Patients with diabetes from Denmark with first-time stroke-related hospitalizations and subsequent mortality were identified from population-based medical databases (12,620 patients). SSRI use was categorized as current, former, or nonuse based on redeemed prescriptions.

The researchers found that 30-day stroke mortality was 15.8 percent among SSRI nonusers (10.4 percent for , 41.8 percent for intracerebral stroke, and 27.3 percent for ). Thirty-day stroke-mortality was 23.3 percent among current SSRI users (17.1 percent for ischemic stroke, 50.7 percent for intracerebral hemorrhage, and 28.6 percent for subarachnoid hemorrhage). Compared with nonuse, current SSRI use correlated with increased 30-day stroke mortality (adjusted mortality rate ratio [MRR], 1.3), with the highest risk for new users (MMR, 1.5). Increased mortality due to ischemic stroke was the driver behind overall , with adjusted MRRs of 1.3 and 1.7 for current and new users, respectively.

"In with diabetes, preadmission SSRI use was associated with increased mortality following ischemic stroke, compared with nonuse," the authors write.

Various companies, including Novo Nordisk, provided research grants to Aarhus University.

More information: Abstract
Full Text (subscription or payment may be required)

Journal information: Journal of Internal Medicine

Copyright © 2016 HealthDay. All rights reserved.

Citation: Preadmission SSRI use ups stroke mortality in diabetes (2016, May 9) retrieved 21 February 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Well-managed warfarin therapy associated with low risk of complications in patients with atrial fibrillation


Feedback to editors